Lexicon Pharmaceuticals | LXRX - Gross Profit On Sales


Lexicon Pharmaceuticals reported $5.29M in Gross Profit on Sales for its fiscal quarter ending in December of 2025.





Gross Profit On Sales Change Date
Abbott USD 5.86B 675M Mar/2026
Acadia Pharmaceuticals USD 243.27M 14.49M Mar/2026
Agios Pharmaceuticals USD 19.43M 1.34M Mar/2026
Akebia Therapeutics USD 47.28M 1.7M Dec/2025
Alnylam Pharmaceuticals USD 825M 4.3M Mar/2026
AstraZeneca USD 12.61B 225M Mar/2026
BioMarin Pharmaceutical USD 571.21M 141.8M Mar/2026
Coherus Biosciences USD 8.7M 853K Dec/2025
Eli Lilly USD 15.92B 1.33B Dec/2025
Esperion Therapeutics USD 140.59M 94.57M Dec/2025
Halozyme Therapeutics USD 297.47M 75.53M Mar/2026
Illumina USD 721M 38M Mar/2026
Insmed USD 256.46M 38.78M Mar/2026
Ironwood Pharmaceuticals USD 85.24M 44.1M Jun/2025
J&J USD 17.24B 642M Mar/2026
Lexicon Pharmaceuticals USD 5.29M 8.88M Dec/2025
MacroGenics USD 31.11M 30.14M Dec/2025
MannKind USD 68.33M 9.98M Mar/2026
Merck USD 10.85B 2.57B Dec/2025
Moderna USD -566M 792M Mar/2026
Novartis USD 10.07B 184M Mar/2026
PTC Therapeutics USD 232.94M 84.56M Mar/2026
Puma Biotechnology USD 20.32M 24.85M Sep/2024
Sarepta Therapeutics USD 621.34M 577.79M Mar/2026
Thermo Fisher Scientific USD 4.49B 146M Mar/2026
Ultragenyx Pharmaceutical USD 106M 72M Mar/2026
United Therapeutics USD 315.5M 286.6M Dec/2025
Vanda Pharmaceuticals USD 50.6M 5.5M Dec/2024